PCM Encore LLC Buys New Shares in Thermo Fisher Scientific Inc. $TMO

PCM Encore LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,398 shares of the medical research company’s stock, valued at approximately $701,000.

Several other large investors have also recently added to or reduced their stakes in TMO. High Note Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $28,000. Legacy Wealth Managment LLC ID lifted its position in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the period. Birchwood Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth $29,000. Finally, Core Wealth Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $71,191,194.75. This trade represents a 7.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 63,493 shares of company stock worth $37,657,681. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $628.24 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The stock has a market capitalization of $232.29 billion, a PE ratio of 33.79, a PEG ratio of 2.50 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock’s fifty day moving average is $539.33 and its 200-day moving average is $508.86.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.11%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TMO shares. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective on the stock. Weiss Ratings upgraded Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.